Search ↗

Comparison

5-Amino-1MQ vs MOTS-c

5-Amino-1MQ is fat loss; MOTS-c is mitochondrial & longevity. They are compared here because they are frequently considered against each other, not because they act alike.

On published evidence alone, MOTS-c is the better documented of the two (preliminary human). That is a statement about the state of the literature, not a recommendation.

5-Amino-1MQ MOTS-c
Class Fat loss Mitochondrial & longevity
Evidence Animal models only Preliminary human
Human trials None published ~3
Half-life ~4-6 hours ~1-2 hours
Reported range 50-150 mg 5-10 mg
Frequency Once daily 2-3x weekly
Routes Oral Subcutaneous, Intramuscular
FDA approved No No
Research use only Yes Yes
Banned in sport No No
Studied for Adipocyte metabolism research, NAD+ pathway research Metabolic health research, Insulin sensitivity, Exercise capacity research, Longevity
Reported side effects Insomnia, Nausea, Headache Injection-site reactions, Transient fatigue, Headache

5-Amino-1MQ

5-Amino-1MQ is a quinolinium small molecule that inhibits nicotinamide N-methyltransferase, an enzyme highly expressed in white adipose tissue. Inhibiting NNMT raises intracellular nicotinamide and NAD+ and has been reported to reduce adipocyte size and increase energy expenditure in rodent models. There is no published human trial data. It is listed here because it is sold and discussed as a peptide, which it is not.

MOTS-c

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene rather than in nuclear DNA, which makes it unusual among signalling peptides. It regulates the folate-methionine cycle, leading to accumulation of AICAR and consequent AMPK activation, shifting metabolism toward glucose uptake and fatty acid oxidation. Exercise raises endogenous MOTS-c, and levels fall with age, which is the basis of both the exercise-mimetic framing and the longevity interest. Human trial data is limited.

5-Amino-1MQ vs MOTS-c: common questions

What is the difference between 5-Amino-1MQ and MOTS-c?

5-Amino-1MQ is fat loss and MOTS-c is mitochondrial & longevity, so they act on different pathways. 5-Amino-1MQ: A small-molecule NNMT inhibitor studied for adipocyte metabolism. Not a peptide, despite how it is sold. MOTS-c: A mitochondria-encoded peptide that acts as an exercise mimetic through AMPK, and one of the better-characterised mitochondrial-derived peptides.

Which has stronger evidence, 5-Amino-1MQ or MOTS-c?

MOTS-c has the stronger evidence base (preliminary human, about 3 human studies) compared with 5-Amino-1MQ (animal models only).

Are 5-Amino-1MQ and MOTS-c FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  2. PubChem compound record (CID 146675088) ↗ · structure, identifiers, synonyms

Published literature

  1. Yang M, Wang B, Hou W, et al.. NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer.J Immunother Cancer 2024.PubMed 39067875 · doi:10.1136/jitc-2024-009281
  2. Dimet-Wiley A, Wu Q, Wiley JT, et al.. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Sci Rep 2022.PubMed 35013352 · doi:10.1038/s41598-021-03670-5
  3. Akar S, Duran T, Azzawri AA, et al.. Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.J Obstet Gynaecol 2021.PubMed 33645410 · doi:10.1080/01443615.2020.1854696
  4. Zhang Z, Chen D, Du K, et al.. MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria.Mitochondrion 2023.PubMed 37307934 · doi:10.1016/j.mito.2023.06.002
  5. Mohtashami Z, Singh MK, Salimiaghdam N, et al.. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.Int J Mol Sci 2022.PubMed 36233287 · doi:10.3390/ijms231911991
  6. Amado CA, Agüero J, García-Unzueta M, et al.. MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases.J Transl Med 2026.PubMed 42243958 · doi:10.1186/s12967-026-08398-2
  7. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.Free Radic Biol Med 2016.PubMed 27216708 · doi:10.1016/j.freeradbiomed.2016.05.015
  8. Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.Front Endocrinol (Lausanne) 2023.PubMed 36761202 · doi:10.3389/fendo.2023.1120533
  9. Mendelsohn AR, Larrick JW. Mitochondrial-Derived Peptides Exacerbate Senescence.Rejuvenation Res 2018.PubMed 30058454 · doi:10.1089/rej.2018.2114
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  11. Cuyàs E, Verdura S, Martin-Castillo B, et al.. Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging (Albany NY) 2022.PubMed 36490309 · doi:10.18632/aging.204423

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.